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Suicide among United States veterans is a serious public health concern. Among the 
known risk factors for suicidal ideation and suicide among veterans are mental health 
conditions, including post-traumatic stress disorder and depression, and opioid use 
disorder. Opioid prescriptions continue to rise in the United States, so does opioid use 
disorder and overdose deaths. However, it is not known if opioid prescriptions are 
associated with an increased risk of suicidal ideation in veterans A retrospective cohort 
study is proposed to determine whether opioid prescribing at Veterans Affairs 
hospitals and health centers correlates with rates of suicidal ideation. Veterans 
prescribed opioids will be stratified by morphine equivalent daily dose and then assessed 
for Columbia-Suicide Severity Rating Scales performed as secondary patient screenings. 
This study will provide essential insights to help identify veterans who are at increased 
risk for suicidal ideation. 
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CHAPTER 1: INTRODUCTION 
1.1 BACKGROUND 
A 2017 report published by the Office of Suicide Prevention from the Department of 
Veterans Affairs (VA) showed the suicide rate among veterans was 39.2 suicides per 
100,000 person-years in the United States, while the non-veteran population had a suicide 
rate of 21.6 suicides per 100,000 person-years1. Several risk factors for suicidal ideation 
have been identified in the veteran population. The most significant risk factor for 
suicidal ideation is Post Traumatic Stress Disorder (PTSD)2-4, though there are many 
others such as depression2,3,5,6 and other psychosocial disorders such as anxiety6-8. Some 
factors are directly related to service such as deployment conditions6,9, training10, and 
post-deployment stressors11, which have been associated with increased suicidal ideation 
in returning Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) 
veterans.  
 Though there have been significant advancements in the collective understanding 
of risk factors for suicidal ideation and completion within veterans, veterans still carry an 
increased risk for suicide compared with civilians.12,13 This highlights the need for 
additional research to better identify high-risk veteran populations. It has been 
demonstrated that veterans, especially those with comorbid mental health disorders like 
PTSD and depression, are more likely to receive opioids and, when they do, receive 
opioids at higher and more dangerous dosages14.  This population is already at higher risk 
for suicide based on mental health comorbidities, and this proposed study aims to assess 
whether receiving opioids enhances the likelihood of a positive suicide risk screen, and 
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whether suicidal ideation risk increases with increasing morphine equivalent daily dosing 
(MEDD). 
 Understanding the risk factors associated with suicidal ideation and completion is 
essential for any clinician. The veteran population is at significantly increased risk of 
suicidal ideation, planning, and of suicidal completion.15-17 Because of the elevated risk 
for suicide in the veteran population, the VA administers suicide screening assessments 
to any veteran in conjunction with mental health screens. The VA clinical reminder for 
depression screening (PHQ2) found in appendix A, is a required annual screen for all 
Veterans (and includes a third suicide screening question Item-9). Similarly, the Primary 
Care PTSD Screen (PC-PTSD-5) found in appendix B is administered to all veterans 
annually for five years, and then every five years after that (and includes a fifth suicide 
screening question Item-9). 
In addition to mental health risks, veterans often have complex medical and 
psychosocial issues that require special consideration18. Many Operation Iraqi Freedom 
and Operation Enduring Freedom veterans return from active service with chronic pain 
and other musculoskeletal concerns, from both wounds received from enemy contact as 
well as from the intense physical stress of many military specialties18. The initial standard 
of care for wounds sustained from enemy contact (including improvised explosive 
devices as well as direct enemy engagement) was to provide opioid pain relief19. Veterans 
are more likely to have chronic pain compared with non-veterans and are more likely to 
receive opioids and higher risk opioids compared with non-veterans20. Though these 
practices have been changing in recent years with the addition of complementary and 
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alternative treatments such as battlefield acupuncture, a large portion of returning 
veterans received opioids. 
 One of the potential complications that have not been thoroughly studied is the 
relationship between opioid prescriptions in the VA and positive suicide risk screening 
assessments performed at the VA. The relationship between opioid misuse and suicide 
risk as well as opioid use and suicide risk has been studied previously21-24; these studies 
show a clear relationship between increasing opioid use and suicide as well as increasing 
MEDD and prescriptions that are filled more often and suicide completion. However, it 
has not been shown if there is a relationship between prescribing patterns in the VA and 
suicide risk. The administration of buprenorphine in suicidal opioid-dependent patients 
has been shown to lower the risk of suicidal ideation25,26, which suggests there may be a 
link between untreated opioid dependence and suicidal ideation. 
This is pertinent to the practice of PAs, as patients with chronic pain, and those 
co-morbid mental health concerns, would be familiar to see in the scope of practice.  US 
veterans make up 8 percent of the US population27, which means PAs practicing both 
inside and outside of the VA system would need to have a basic understanding of the 
health risks faced by this unique population.  PAs currently prescribe 11% of opioid 
prescriptions in the US in generalist settings28, and when prescribing, suicide assessment 
is not routinely addressed.   Though data demonstrate a lack of efficacy of opioids in the 
treatment of chronic pain29, there remains a population of patients on chronic opioids who 
have “grandfathered” into opioid medications and who have been unable to taper off of 
them, including veterans with comorbid PTSD/Depression.  This study would be 
essential to identify this subset of patients who may be at augmented risk for suicide such 
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as those with chronic pain conditions and other comorbid conditions that are not regularly 
screened at the VA.  
Some ethical considerations would need to be addressed for a study like this 
include a need to ensure that patients who are prescribed opioids are not stigmatized 
about the potential suicide risk. One of the most effective mitigation tools for suicide risk 
is to destigmatize talking about and treating suicide risk, and anything that has the 
potential to increase that stigma needs to be handled carefully. Secondly, the results of 
the study would need to be carefully evaluated. If an increased risk of suicidal ideation is 
shown with opioid prescriptions, and there is an association of suicidal ideation with 
higher dosages, then it could lead to some providers discontinuing prescribing opioids 
without appropriate taper or alternatives. It has been shown that patients on chronic 
opioids who are stopped abruptly are at increased risk for both unintentional overdose, 
seeking illicit prescriptions, and suicide30. It might also further stigmatize opioid use in 
patients receiving end of life care. These ethical concerns will need to be addressed with 
the VA IRB before the study can be conducted. 
 
1.2 STATEMENT OF THE PROBLEM 
 The association between opioid prescriptions and suicidal ideation has not been 
adequately studied in the OEF/OIF veteran population. There are currently no screening 
protocols for veterans who do not have a history of suicidal ideation, suicide attempts, 
PTSD, or depression. It is worthwhile to explore the association between opioid 
prescriptions and suicidal ideation to see if screening tools that are in place for other 
veterans with diagnosed mental health conditions would be appropriate for all veterans 
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receiving opioid therapy. It may also be useful in identifying underlying undiagnosed 
comorbid mental health conditions commonly associated with chronic pain.  
1.3 GOALS AND OBJECTIVES 
This retrospective cohort study seeks to investigate the effect of opioid 
prescriptions on suicidal ideation in Operation Iraqi Freedom and Operation Enduring 
Freedom veterans. All OEF/OIF veterans who have received a Columbia Suicide Severity 
Rating Scale assessment (C-SSRS) (appendix C) who live in states with prescription drug 
monitoring programs (PDMPs) and whom either have received no opioid prescriptions or 
who have received them within the last 180 days will have records evaluated in this 
study. Those veterans who received no opioids at the time of screening will serve as the 
negative control group. Those veterans who were prescribed opioids within 180 days of 
their C-SSRS assessment will have their prescriptions converted into morphine 
equivalent daily doses (MEDDs) and will be stratified by these MEDDs. This study will 
evaluate the years 2011-2018. 
1.4 HYPOTHESIS 
Among OEF/OIF veterans who received an opioid prescription within the last 180 
days, there will be a statistically significant increase in rates of suicidal ideation as 
measured by positive C-SSRS assessments with increasing MEDD of prescribed opioids 
when compared with OEF/OIF veterans who received no opioid prescriptions during the 
years 2011-2018. 
1.5 DEFINITIONS 
OIF: Operation Iraqi Freedom. March 2003-November 2011, operation name for US war 
in Iraq 
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OEF: Operation Enduring Freedom. October 2001-December 2014, operation name for 
US war in Afghanistan. 
MEDD: Morphine equivalent daily dose. The MEDD converts the dose and route of each 
opioid a patient has received over the last day to a morphine equivalent using a standard 
conversion known as the morphine milligram equivalent.  
C-SSRS: Columbia Suicide Severity Rating Scale. The C-SSRS is a well-validated tool 
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CHAPTER 2: REVIEW OF THE LITERATURE 
2.1 INTRODUCTION AND METHODOLOGY 
An exhaustive literature search was conducted between July 2019 and March 
2020 using MEDLINE, Ovid, PubMed, Scopus, and Cochrane. Primary searches were 
performed using the combination of MeSH terms [Analgesics, Opioid] [Veterans] 
[Suicide] and [Suicidal Ideation] Other search terms included [Drug Prescriptions] [Drug 
Overdose] [Opioid Related Disorders] [Opioid Mortality] [United States Department of 
Veteran Affairs] [Guideline Adherence] and [Practice Patterns]. Study populations were 
limited to those above the age of eighteen. Clinical studies were prioritized, systematic 
reviews, and meta-analyses. Through analysis of abstracts and titles, the relevance of 
articles was determined, then obtained the full articles, and those articles were analyzed 
for inclusion within the literature review. Throughout the primary literature search, 
additional references were extracted from the reference section of previously identified 
articles as well as MEsH terms and were added to the literature review and the literature 
search, as was appropriate.  
2.2 REVIEW OF EMPIRICAL STUDIES 
2.2.1 Suicidal ideation in veterans 
  In the most recently released VA data (2017), there were approximately 17 
veteran suicides a day1 making suicide a major public health concern. Multiple factors 
influence veteran suicide rates and are involved with suicidal ideation. Some of these 
factors are unique to veterans, such as combat exposure2, while others such as PTSD and 
depression, are not unique but much more prevalent in the veteran population.3 Many 
veterans will also return from active duty and deployments with significant social and 
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economic concerns, which can further increase the risk for suicidal ideation. The 
following literature review establishes what factors are the largest influencers of suicidal 
ideation and suicide completion in veterans and what risks distinguish veterans from 
civilians. 
 Veteran suicide has always been a major concern for the VA, but in recent years 
rates of suicide have reached their highest numbers since the VA started tracking data on 
veteran suicides1. For the past several years, a growing body of data has allowed the VA 
to better identify veterans who are at risk for suicide and for conditions like PTSD and 
depression, which are known to increase suicidal ideation. One common theme among 
these studies is that factors known to increase suicidal ideation in civilians will also 
increase suicidal ideation in veterans4, which, while unsurprising, allows studies that may 
be otherwise not applicable to the veteran population. This evidence has led the VA to 
initiate several universal and selected screenings such as the Patient Health 
Questionnaire-2 (PHQ-2). The PHQ2 is a two-question screening tool for depression that 
asks, “Over the last two weeks, how often have you been bothered by the following 
problems: Little interest or pleasure in doing things. Feeling down, depressed, or 
hopeless”, this is also found in appendix A. The VA also implemented the Primary Care 
PTSD Screen for DSM-5 (PC-PTSD-5) which asks “In the past month have you: had 
nightmares about the event(s) or thought about the event(s) when you did not want to, 
tried hard not to think about the event(s) or went out of your way to avoid situations that 
reminded you of the event(s), been constantly on guard, watchful, or easily startled, felt 
numb or detached from people, activities, or your surroundings, felt guilty or unable to 
stop blaming yourself or others for the event(s) or any problems the event(s) may have 
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caused” this is also found in appendix B. In 2020 the Item 9 question “Do you have 
thoughts that you would be better off dead or hurting yourself in some way?” was added 
to the screening for all VA patients. A positive to any of these screening tools elicits 
further screening with the Columbia-Suicide Severity Rating Scale, which assesses for 
suicidal ideation.  While the VA focuses on assessing for suicide risk in the context of 
PTSD and depression, several other important factors have been shown to increase 
suicidal ideation. Factors that increase the risk of suicidal ideation include chronic pain5-7, 
previous sexual and physical abuse8,  and psychosocial issues such as poor personal 
relationships, financial difficulties, and professional issues9. Despite being a common risk 
factor for suicide, chronic pain conditions do not prompt routine suicide screening at the 
VA.  
2.2.2 Chronic pain conditions and suicidal ideation 
 Chronic pain is a widely recognized risk factor for suicidal ideation and suicide 
completion 5-7,10-13. The idea that chronic pain and suicidal ideation may be linked was 
first proposed in a 1992 paper by Breslau14, where they recruited 128 patients who 
suffered from migraines to see if they had any psychosocial issues relating to their 
migraines. They found that patients with migraine with aura and depression had higher 
rates of suicidal ideation than those with depression alone. They also found that those 
with migraine and aura without depression had increased rates of suicide attempts. The 
study had several limitations since they did not look at patients with migraine without 
aura, and they only looked at a one-item question of whether the patient had any current 
suicidal ideation. This early work paved the way for further studies, which included a 
199415 study that evaluated 635 orthopedic patients who were referred to a pain 
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assessment service and followed for 12 months. These patients were stratified by how 
long they were in pain, in groups from 0-3 months, 4-6 months, 7-9 months, 10-12 
months, and greater than 12 months. Patients were evaluated for several endpoints, 
including joblessness, depression, anxiety, and suicidal ideation. They found that the 
longer the pain lasted, the greater the reported suicidal ideation (p=0.013). In contrast, a 
history of suicide attempts prior to pain onset was not significantly associated with 
suicidal ideation (p=0.52), showing that the pain was the primary driver of their suicidal 
ideation. A major limitation of this study was that it included many patients (n=280) who 
had acute or sub-acute pain (0-3months), making it less generalizable to patients with 
chronic pain conditions. Chronic pain is defined as pain lasting longer than three to six 
months16. The study was still able to demonstrate that in patients suffering from more 
than three months of pain did have increased suicidal ideation, which was an important 
finding. Additionally, both studies were able to find a link to different types of pain and 
suicidal ideation, which was able to set the groundwork for more comprehensive studies 
to investigate this phenomenon. 
 Neither of these studies had suicidal ideation as their primary endpoint, so in 2001 
a landmark paper was published by Fisher et al. 17 that evaluated 200 patients admitted to 
the inpatient chronic pain rehabilitation program. They evaluated the patients with two 
questions from the Beck Depression Inventory(BDI): “I would like to kill myself” and “I 
would kill myself if I had the chance” The BDI is a well-validated exam for depression 
and suicidal ideaiton18 so the study by Fisher et al. provides good insight to suicidal 
ideation in this patient population. They found that pain severity (p=0.01), physical 
functioning (p=0.02), and a self-appraisal of pain (p=0.02) were all significant risk 
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factors for suicidal ideation. While passive coping strategies such as praying and hoping 
(p=0.53) were not significantly associated with being protective for suicidal ideation. 
Some limitations of this study were the relatively small sample size (n=200), and the 
study design as a non-randomized observational study. This study was important because 
it aimed to identify specific elements of chronic pain that are associated with higher risk 
for suicidal ideation. The investigators were not able to find any single measure that 
increased suicidal ideation, but this study was instrumental in finding that increasing 
chronic pain in both perceptive and analytical metrics increased risk of suicidal ideation. 
 This study was followed up soon after by a 2004 study by Smith et al. 19, which 
recruited 75 patients that had pain for greater than six months, no psychiatric disorders 
including depression, and were not in treatment for any major medical conditions other 
than ones relating to their chronic pain. They also used the BDI to evaluate suicidal 
ideation and found that 24% of enrolled patients had passive or active suicidal ideation. 
Another finding was that the pain intensity rating (p=0.008) and medication usage (0.003) 
were both significant risk factors for suicidal ideation. This study also evaluated the 
patients' sleep quality (p=0.06) and sleep duration (p=0.72), neither of which was found 
to be a significant contributor to suicidal ideation. This study was useful in trying to 
understand further why chronic pain might cause suicidal ideation. This study was 
limited by its small sample size and lack of follow up, but they did exclude patients who 
had pain for less than six months to ensure that only patients suffering from chronic pain 
were evaluated. While they were unsuccessful in showing that sleep influenced suicidal 
ideation, this study, along with the Fisher et al.17 study, was another critical study 
showing that chronic pain without depression can increase suicidal ideation. More 
 15 
importantly, this study showed a clear relationship between treatment for chronic pain 
and suicidal ideation, which had not been previously established. 
 Though only recently investigated chronic pain is an important factor in suicidal 
ideation. One of the most common20, though often misguided21, treatments for chronic 
pain is opioid therapy.  
2.2.3 Opioid dosages and their risk of overdose 
 Opioids have long been used to treat both acute and chronic pain. Although there 
is strong evidence suggesting that opioids are not effective at treating chronic pain21, 
there are still many clinicians who prescribe opioids for chronic pain22. A major risk of 
prescribing opioids for chronic pain is their potential for overdose, both unintentional and 
intentional. In 2011 a major case-cohort study23 using VA data enrolled 5% of all VA 
patients between 2004 and 2005 (n=154,684) and quantified how many had an 
unintentional opioid overdose by 2010. Participants were stratified into 4 groups by 
prescribed morphine equivalent daily dose, 1-<20 mg/day, 20-<50 mg/day, 50-<100 
mg/day and >100 mg/day. They found that increasing opioid prescriptions led to an 
increased risk of overdose in the following five years. Using 1-<20 mg/day as their 
reference group (HR=1) 20-<50 mg/day was the first study group (HR=1.88), 50-<100 
mg/day was the second study group (HR=4.53), >100 mg/day was the third study group 
(HR=7.18) all study groups showed a significantly higher rate of overdose when 
compared with the reference group (95% CI). The study was limited by its small sample 
size of actual overdose deaths (n=750), and the fact that overdose deaths were a relatively 
rare outcome among all enrolled participants (0.04%-0.45%). Nevertheless, this study 
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was critical in showing that there is a clear relationship between morphine equivalent 
daily dose and overdose risk in the veteran population.  
 While the previous study was in its follow up period, another study was looking at 
patients with chronic pain conditions and their risk of overdose. In this 2010 study24, 
9940 participants were enrolled who had received three or more opioid prescriptions 
within 90 days for pain between the years 1997 and 2005. This study stratified patients by 
their morphine equivalent daily dose in the same way as the previous study and found 
similar results. They again used the 1-<20 mg/day group as their reference (HR=1) in the 
20-<50 mg/day (HR=1.44), 50-<100 mg/day (HR=3.73), >100 mg/day (HR=8.87) and 
showed that increasing morphine equivalent daily doses led to increasing rates of 
overdose in a non-veteran population with chronic pain. This study, as with the previous 
study, had a major limitation in that they were only able to assess the prescription of 
opioids and not the patterns that the patients took these medications. However, the 2010 
study24 did not account for the amount of chronic pain, which has been shown to affect 
suicidal ideation, which can also lead to an overdose death. The combination of these two 
studies showed a clear and dangerous effect of increasing opioid prescriptions in patients 
both with and without chronic pain25.  
 The well-studied concept that increasing opioid prescriptions can lead to 
increased rates of unintentional overdose is not a surprising conclusion. However, this 
brings up the question of the role of opioids in suicidal ideation as access to lethal means 
increases with increasing prescriptions. 
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2.2.4 Opioids and risk of suicidal ideation  
 Chronic pain as a driver for suicidal ideation, and increased opioid prescribing for 
chronic pain conditions, makes for a dangerous combination. Additionally, increasing 
opioid prescriptions leads to increased risk for development of an opioid use disorder and 
risk for unintended overdose. It was shown in studies like Kuramoto et al. 26 there is an 
increased risk of suicidal ideation and suicide attempt among people who use non-
prescription opioids. It can also be seen that opioid misuse has a positive correlation with 
suicidal ideation and suicide attempts in studies like Ashrafioun et al.27 
The access to lethal means and their impact on suicidal ideation has not been well 
studied, but there is ample evidence that reduction of access to lethal means reduces 
completed suicides28-30. However, despite the abundant evidence that having lethal 
means, opioid misuse, and chronic pain all increase the risk of suicidal ideation and 
completion, there are very few studies that examine the role of opioid prescriptions as a 
possible driver or even surrogate for other conditions that increase suicidal ideation.  
 The largest study that examines the relationship between opioid dose and suicide 
is a 2016 paper by Ilgen et al.31. This case-cohort paper took a 5% sample of all VA 
patients between the years 2004 and 2005 (n=123,946) and followed the cohort until 
2009. The primary endpoint for this study was suicide completion, as assessed by death 
records at the VA and state/county level. Patients were matched to case controls by sex, 
age, race, physical conditions including COPD, chronic pain, neuropathy, and psychiatric 
conditions such as depression, anxiety, PTSD, psychosis, and finally, by the Charlson 
comorbidity index score. Patients were stratified into five groups, similar to previous 
studies looking at opioid prescriptions, based on morphine equivalent daily dose. The 
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groups were: 0 mg morphine equivalent daily dose, which served as the control, 1-<20 
mg/day which was group 1, 20-<50 mg/day which was group 2, 50-<100 mg/day which 
was group 3 and >100 mg/day which was group 4. They found that the rate of suicide 
completion per 100,000 person-years increased with increasing MEDD (all results 95% 
CI). The control group (0 mg/day) had a rate of 44.4 suicides per 100,000 person-years 
(42.3, 46.5), 1-<20 mg/day (group 1) 42.8 suicides per 100,000 person-years (37.3, 48.7), 
20-<50 mg/day (group 2) 63.9 suicides per 100,000 person-years (57.7, 70.3), 50-<100 
mg/day (group 3) 75.5 suicides per 100,000 person-years (63.2, 88.9) >100 mg/day 
(group 4) 105.0 suicides per 100,000 person-years (88.4, 123.1). Subgroup analysis was 
performed based on fill types of prescriptions with three groups: “regularly scheduled 
fills only,” “as needed,” and “regularly scheduled and as needed simultaneously.” They 
found the “as needed only” group had the lowest rate of 54.9 suicides per 100,000 
person-years (50.1, 59.9), then the “regularly scheduled only” group at a rate of 67.9 
suicides per 100,000 person-years (60.4, 76.0), and finally the “as needed and regularly 
scheduled simultaneously” group with a rate of 90.1 suicides per 100,000 person-years 
(73.7, 108.2). There are some major drawbacks to this study; first, while the cohort was 
large overall, the number of suicides was relatively small (n=2601, 2% of total cohort had 
outcome), and among those, the majority were never prescribed opioids (n=1716, 66% of 
all outcomes) and were in the control group. A study that looks at all veterans receiving 
opioids who are matched to those without would be able to recruit more participants if 
the timeframe were expanded beyond two years. Secondly, they did not assess chronic 
pain intensity or duration, but only matched participants based on whether they had a 
diagnosis of chronic pain. It has been demonstrated in previous studies that chronic pain 
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intensity and duration are associated with increased suicidal ideation. This is likely due to 
limitations in the feasibility of extracting these datapoints as it would require manual 
chart review. Another flaw of this study is that they were not able to determine any 
causality as to why increasing opioid prescriptions would lead to increased suicidality, 
only that the relationship exists. The Ilgen et al. paper was a preeminent study since it 
was the first to look directly at opioid prescriptions and suicidality in veterans while 
controlling for many important factors like PTSD, depression, anxiety, chronic pain, and 
comorbid conditions. It demonstrates that just the opioid dose and the prescription fill 
type can have a major effect on suicidality, which had previously not been studied.  
 With chronic pain being a major for factor in suicidal ideation, there is a need for 
system enhancements that prompt assessment of this risk in the chronic pain population. 
Opioids, an unfortunately common method for treating chronic pain, come with multiple 
risks, including unintentional overdose. One potential risk, as seen in the 2016 Ilgen 
study, is increasing suicidal ideation though this mechanism is still unknown. The 
evidence suggests that increasing opioid prescriptions may act a marker for some 
unknown factor or condition that increases suicidal ideation.  
2.3 REVIEW OF STUDIES FOR CONFOUNDING VARIABLES 
 As previously shown, many variables can influence suicidal ideation, including 
chronic pain, PTSD, and depression. The best way in a cohort study to minimize 
confounders are to match participants as well as possible to not only demographic factors 
but also to physical and psychological characteristics. Statistical methods, such as 
stratification and multivariate models such as logistic regression and ANCOVA, can be 
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used to decrease the potential for known and unknown confounders interference with the 
results of the study32.  
 The most important potential confounder for this proposed study will be chronic 
pain since it is so closely tied with opioid prescriptions and with suicidal ideation. To 
control for this confounder, only participants who have had chronic pain for at least six 
months, to ensure that it truly is chronic, will be accepted. These participants will be 
matched to others who have similar lengths of chronic pain to reduce the confounding 
that Smith et al.19 found that increasing length of time since chronic pain diagnoses leads 
to increasing suicidal ideation. Other factors, such as PTSD, depression, and anxiety, are 
easily matched using VA databases that are covered in the following section.  
2.4 REVIEW OF RELEVANT METHODOLOGY 
2.4.1 Study Design 
 Given enough time and resources, the ideal study design would be a randomized 
control trial. However, aside from the ethical concerns of assigning participants to take 
different amounts of opioids and seeing if it increases their likelihood of suicidal ideation, 
it is not feasible to perform in a two-year time frame that this study is limited. Instead, a 
retrospective or historical cohort is the best choice.  
 There are no studies that evaluate opioid prescriptions and suicidal ideation in a 
retrospective cohort, but there are several studies that evaluate chronic pain in this 
manner6,7,12,33,34 as well as opioid overdoses23,24. While some studies used a case-control 
design25,31, these studies are non-selective in their initial group of participants and are left 
with sample sizes more than 100,000 participants but with insufficient numbers of 
participants with their outcome of interest. Selecting the cohort in a retrospective study 
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allows the study to reduce the burden and time it takes to evaluate all the data since all 
the participants are known, the minimum criteria will be met for the study.  
 Morphine equivalent daily doses will be calculated based on existing standards 
outlined by the VA as well as based in the literature studying opioid overdoses and 
suicidality concerning opioid dose23,24,31. A summary of this calculation is found in 
appendix D 
2.4.2 Study Setting 
 Since the participants will all be veterans, the setting that makes the most sense is 
the VA health system. Inpatient and outpatient settings would be included since previous 
studies in chronic pain, and suicidal ideation showed no difference between the two.5,6 
Additionally, patients that will be enrolled will be prescribed in both inpatient and 
outpatient settings within the VA.  
2.4.3 Selection Criteria 
 Participants for this study will consist of all Operation Enduring Freedom and 
Operation Iraqi Freedom veterans who have received an opioid prescription and were 
administered a C-SRSS for any reason. Previous studies did not exclude participants for 
having comorbid conditions such as PTSD6,23,31 depression6,31,35 and importantly, chronic 
pain6,23,31. Instead, these factors were controlled through matching and statistical analysis 
that will be further covered in chapter 3. Detailed inclusion and exclusion criteria will 
also be included in chapter 3.  
2.4.4 Exposure 
 The timing of when a participant was exposed and when they received testing in a 
retrospective trial is a difficult question to answer without the data. It is possible, 
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however, to look to other retrospective trials and case-control trails to see when they 
measured their outcome and what their follow up periods were for their cohorts. In the 
2016 Ilgen et al.31 paper, their case-control group was from 2 years and was followed up 
on at the cohorts four-year mark. Some data21 suggests that adverse events from opioid 
therapy occur within a year and that it may be as soon as six weeks. A study in 200736 
showed there was no data that continuing opioid therapy for more than 16 weeks was 
effective at treating pain conditions and only led to increased adverse outcomes. 
Ultimately the timing of the study will have to rely on what these data can show us to 
when the expected result will be, but previous studies do show it would be within a year 
of initiation of opioid treatment and possibly as quickly as six weeks.  
 Some previous studies have used case-control methods and sample a randomized 
group from within all VA patients during certain fiscal years23,31.  This method has been 
popular in the past since, even with these restrictive criteria, they can generate large 
sample sizes (n=123,946)31 and (n=154,684)23 and have all the data available to them 
through the VA. The restrictions on this, however, is that they are unable to determine if 
there are any longer-term effects and they are only able to create small samples within 
their larger groups that have the exposure of interest. VA systems have been improved 
over the last decade and it is now possible to use tools like Suicide Prevention Population 
Risk Identification and Tracking for Exigencies (SPPRITE), VA Stratification Tool for 
Opioid Risk Management database (STORM), and the VA National Patient Care 
Database (NPCD) which all allow for researchers to better select which participants they 
want to include in their study. All of these tools and their use will be further discussed in 
chapter 3.  
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2.4.5 Outcomes 
 The primary outcome will be the rate of suicidal ideation as measured by the C-
SRSS that has been stratified into five groups, which will be further described in chapter 
3. The C-SRSS has been validated by the basis of a few studies. The first basis to validate 
the C-SRSS is that suicidal ideation and behavior are the highest short- and long-term 
risk factors for suicide. This is supported by Beck et al.37, which sampled 3,701 patients 
seeking psychiatric help and measured current suicidal ideation and then followed the 
patients for four years after. They found that having suicidal ideation at any time was a 
strong predictor for suicidal completion in that time frame (95% CI: 6.64-33.98, 
sensitivity 80%, specificity 78%). This is also supported by Kuo et al.38, who gathered 
data on 3481 residents in Baltimore, MD, which included surveys asking about suicidal 
ideation and followed up after 13 years. They found that suicidal ideation was more 
likely to be associated with suicide attempts and completion (RR-6.09, 95% CI: 2.58-
14.36). The second argument that validates the C-SRSS is that behaviors such as aborted 
attempts or preparation for suicide are predictive of suicide completion, which has been 
well established by multiple papers39-41 and is generally well accepted. The validity of the 
C-SRSS has also been tested in papers such as Posner et al.42 which tested the C-SSRS 
against other measures for suicidal ideation and suicide attempts in multiple settings, a 
treatment study of adolescents who had attempted suicide, a medication trial with 
depressed patients and a study of adults who presented to the emergency department for 
psychiatric care. It has been validated in multiple settings such as psychiatric emergency 
departments43, and using phone assesments44 as well as being administered by non-
mental health staff45 
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 Study recruitment years were decided on the availability of data as well as the 
ability to control for possible confounders. One major confounder that had led us to start 
the cohort in the year 2011 is that is the year when prescription drug monitoring 
programs became widespread across the country in all but three states, Texas, Wyoming, 
and North Dakota. Even with these programs in place, there are still veterans who receive 
opioids from non-VA prescribers46, but the inclusion of PDMP only states, and this more 
recent timeframe can reduce the confounding of potential outside prescriptions.  
2.4.6 Sample Size and Statistical Tests 
 Based on guidelines from Columbia University47, any positive items on the C-
SRSS indicates current and active suicidal ideation. This means that the primary outcome 
should be a dichotomous outcome, namely, did the patient have suicidal ideation at the 
time the C-SRSS was administered. Further discussion of the timing of administration 
will occur in chapter 3. It was demonstrated in the Ilgen study from 201631 that when 
they sampled 5% of VA patients, they were able to find 2,601 completed suicides in a 
four-year follow up. CDC data48 shows that about 3% of people who have suicidal 
ideation will complete a suicide attempt in a given year, and there were 8.3% of suicide 
attempts completed. This means that for the 2,601 completed suicides in the Ilgen study, 
there may have been up to 32,500 individuals who had suicidal ideation in that 
timeframe. While these numbers seem high, they are consistent with an annual survey 
that the Wounded Warrior Project (WWP) sends to all wounded veterans, in this 
population (n=35,908) WWP found that 32.8% of respondents had suicidal ideation in 
the past year49. Estimating the exact sample size will be difficult as 6 million veterans 
used the VA for healthcare in 2016; of those, it is estimated that 688,000 received opioid 
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prescriptions, but it is unclear how many received a C-SRSS without access to VA 
databases.   
 Effect size calculations are based on the above-estimated sample sizes. The effect 
size of the most relevant study, Ilgen et al.31, was 0.021 as calculated by suicide deaths 
(n=2601) of the total sample (n=123,946). The effect size may end up being much larger 
due to the relatively rare nature of completed suicides against those veterans who will 
have suicidal ideation. However, this does not pose an issue to the study since an 
underestimated effect size will lead to an overestimated sample needed for an adequately 
powered study. The proportional exposure group was calculated to be 0.115 from the 
number of veterans who received an opioid prescription in 2017 over the number of 
veterans who received care at VA facilities in 2017. These numbers may again be 
underestimating the exposure group size since opioid prescriptions have been declining in 
recent years at the VA. The underestimating of the exposure group will again serve to 
overestimate the needed sample size to power the study.  
 Statistical analysis for the primary and secondary outcomes will be further 
outlined in chapter three.  
 
2.5 CONCLUSION 
 The above information in this literature review supports a real need for the 
proposed study. There is strong evidence that chronic pain conditions can lead to an 
increased risk of suicidal ideation and that opioids are regularly prescribed for chronic 
pain. The above literature also highlights that there may be a link between opioid 
prescribing practices and an increased risk of suicidal ideation and suicide completion. 
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There is also ample evidence that veterans are at higher risk than the general population 
for suicidal ideation and suicide completion, which highlights the importance of the 
group presented in this study. This shows a clear need for a way to quickly and easily 
identify patients that potentially have an increased risk of suicidal ideation since these are 
the same patients that have increased risk for suicide completion. This study will show 
where improvements to existing screening tools can be made. Additionally, it will add to 
the body of literature that will enhance where the VA and other practice settings can 
benefit from directed and automated screenings to more easily place patients into 
appropriate treatment. The study that will be outlined in chapter 3 will retrospectively 
evaluate veterans using existing screening tools that the VA has at their disposal to keep 
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CHAPTER 3: STUDY METHODOLOGY 
3.1 STUDY DESIGN 
 This proposed study is a Veteran Health Administration wide retrospective cohort 
study within the Department of Veterans Affairs that will investigate the association 
between morphine equivalent daily doses and increasing suicidal ideation, as measured 
by the C-SRSS, in Operation Enduring Freedom and Operation Iraqi Freedom veterans 
who received an opioid prescription within the last 180 days in the years 2011-2018. Due 
to the nature of the study, there will be no blinding, and the participants will not be 
notified of their inclusion in the study. Data will be sourced from the VA and state 
PDMPs, and no identifiable information will be shared with state agencies other than to 
match PDMP records to VA records.  
3.2 STUDY POPULATION AND SAMPLING 
 This study will enroll all OEF/OIF veterans who have received an opioid 
prescription between the years 2011 and 2018 from the Veterans Health Administration 
(VHA) and who live in states with PDMPs. The states excluded will be Texas, North 
Dakota, and Wyoming, as none of these states had PDMPs. 
Inclusion criteria will be all OIF and OEF veterans who have received care 
through the Veterans Health Administration during the period of the study and who 
received an opioid prescription and, within 180 days, had a mental health screening.  
Exclusion criteria will be veterans with a current substance use disorder, veterans who 
have received hospice or palliative care or who received consultations for hospice or 
palliative care, and veterans with a history of suicide attempts. Veterans will be further 
excluded if they did not have any mental health screening during the timeframe of the 
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cohort, including the PHQ-2, I-9, PHQ-9, or the C-SRSS. Inclusion and exclusion criteria 
are summarized in Table 2.  
 Recruitment into the study will not require any notification to the participants 
since this is a retrospective study, and no intervention will be performed on the 
participants. Sampling for the study will be conducted through the Corporate Data 
Warehouse (CDW) and evaluated using the Capri, Reach Vet, Risk Indicators and Storm 
Tool for Analytic Look Up (CRISTAL) as well as the Opioid Therapy Risk Report 
(OTRR) which are further outlined in the following section.  
3.3 STUDY RECRUITMENT  
Participants will be recruited by using several VA and VHA tools. The first of 
these tools is the Corporate Date Warehouse (CDW). This database contains all VHA 
electronic health records and is the primary source for creating the initial list of 
participants that will be pared down with the tools whose descriptions will follow. The 
CDW is a database that is updated nightly that automatically incorporates all health 
records for the VA. This database is used as the foundation for tools like CRISTAL and 
SPPRITE, which are discussed later. The first tool used to pare down the CDW data is 
the VA Information Resource Center (VIReC) OEF/OIF roster. This database includes all 
veterans who have served in a theater of combat operations in support of Operation 
Enduring Freedom or Operation Iraqi Freedom (later renamed Operation New Dawn). 
This roster will be cross-referenced with the CDW list to make the list of OEF/OIF 
veterans who have received care at the VHA. The next tool is the Defense Manpower 
Data Center (DMDC), which is a Department of Defense maintained database that serves 
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as a secondary check for veterans who would be eligible for OEF/OIF status but were for 
some reason not enrolled.  
The following tools used will identify OEF/OIF veterans who have received 
opioids in the last 180 days and who have received a mental health screening and those 
who have received no opioids but still received a mental health screening. The OTRR is a 
nationwide database (from CDW data) that is updated nightly. This database includes key 
variables and will be used to cross-reference which veterans received an opioid 
prescription during the study period and the date the opioid was prescribed. The database 
will also calculate the morphine equivalent daily dose, their urine drug test results, the 
pain scores, as well as the number of days supply and if it was an as needed or regularly 
scheduled medication. The OTRR will be used to separate the cohort into the exposure 
group, those who received opioid prescriptions in the last 180 days, and the control group 
who received no opioids in the last 180 days. The next tool, CRISTAL, is a relatively 
new tool that uses CDW data without needing input from an investigator to compile 
databases that are easily accessible for studies. Using CRISTAL, the curated list of 
OEF/OIF veterans who have received VHA care and opioid prescriptions will be 
evaluated, and CRISTAL will flag participants that received a mental health screening as 
well as the type of screening and its result. This final list will comprise the study cohort.  
3.4 SUBJECT PROTECTION AND CONFIDENTIALITY 
The Department of Veterans Affairs Central IRB requires that all principal 
investigators and study chairs complete VA central IRB form 108 before any data being 
accessed for research. The VA will also have an assigned local site investigator at the 
West Haven VA, who will oversee that all patient data is handled appropriately. This 
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study will also require the approval of the West Haven VA IRB for site access for data 
storage and access point use. This process is outlined in Appendix E. 
The Yale University Human Investigation Committee and the Yale Human 
Research Program will approve all aspects of the study and will require full records 
throughout the study. All researchers and study personnel will complete HIPPA training 
before the start of the study and maintain active certification throughout the study. 
Electronic information will be maintained on a secure, encrypted platform to ensure the 
safety of patient data. All patient data will be de-identified, and patients will be assigned 
a random number to de-identify them in the cohort database further. All patient 
information will be stored on encrypted VA computer systems that require two-factor 
authentication to access.  
3.5 STUDY VARIABLES AND MEASURES  
 In this retrospective cohort study, the main exposure will be receiving an opioid 
prescription within 180 days of also having a mental health screening. The controls will 
be participants who did not receive any opioid prescriptions in the last 180 days but who 
had a mental health screening. The exposure cohort will be further broken down into four 
groups by MEDD. The first is 1-<20 mg/day, second is 20-<50 mg/day, third is 50->100 
mg/day and fourth is 100+ mg/day.  
 The primary outcome is the rate of positive C-SRSS per 100,000 person-years in 
relation to the MEDD that is prescribed to the participants. This will be a dichotomous 
variable within groups. Secondary outcomes will be the rate of positive C-SRSS per 
100,000 person-years in relation to the prescribing patterns of which there will be three 
groups in this outcome, as needed (PRN) group, regularly scheduled group, and the PRN 
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+ regularly scheduled group. Another secondary outcome will be if there is an association 
between chronic pain diagnosis at the time of receipt of opioid prescription and positive 
C-SRSS, which will be a dichotomous variable. Finally, the last secondary outcome will 
be tracking the rates of completed suicide and matching them to any opioid prescriptions 
and using the above stratification into the control group receiving no opioids and the four 
exposure groups.  
3.6 CONFOUNDING VARIABLES 
 Several confounding variables will be accounted for in this study. Confounders 
will be matched between the control and exposure groups in several categories. The first 
category will be by demographics, which will include sex, age, race, branch of service, 
and if the veteran was an officer or was enlisted. The second category will be physical 
medical issues, which will include a diagnosis of chronic pain, acute pain or injury, 
traumatic brain injury, psychogenic pain, neuropathy, cancer, COPD, and any sleep apnea 
disorders including obstructive sleep apnea. The physical medical issues will also include 
the Charlson comorbidity index, which is an index used to predict ten year survivability1. 
The third category will be psychiatric conditions, which will include diagnosis of 
depression, bipolar disorder, any anxiety disorder, PTSD, and any psychotic disorders. 
The fourth and final category will be concurrent medication use, which will include any 
use of benzodiazepines, SSRIs, SNRIs, and hypnotics. These confounders, as well as the 
above treatment groups, are summarized in Table 1. Further statistical analysis will be 
performed between exposure and treatment groups in both primary and secondary 
outcomes. These analyses will be further outlined in section 3.9 of this chapter.  
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3.7 DATA COLLECTION 
 Methods for sourcing and collecting participant data is outlined in section 3.3 
under study recruitment. Data will be additionally collected for verification using the VA 
Stratification Tool for Opioid Risk Mitigation (STORM), which is a tool that 
automatically flags patients who are at risk for overdose and suicide. This tool extracts 
data on all VA patients who are prescribed opioids, and it will be used as another way to 
extract data from the VA electronic health records without the need for researcher or 
clinician input to identify high-risk patients for subgroup analysis.  
3.8 SAMPLE SIZE CALCULATION 
Raw sample size as estimated from previous VA data showing there were 
approximately 6,000,000 patients seen in VA facilities a year between the years 2011 and 
20182. The estimated exposure size of total patients is 0.115, as calculated by an average 
of 688,000 opioid prescriptions per year during the years 2011 to 20173. The estimated 
effect size is 0.021. There will need to be a minimum of 260,743 total patients evaluated 
in this study to power the study at 80% with an alpha of 0.01. There will need to be a 
sample of 29,986 veterans who received an opioid prescription and a mental health 
screening as well as 230,757 who did not but did receive a mental health screening. A 
summary of these calculations will be in appendix E. 
3.9 ANALYSIS 
 All data collected by CDW and other VA databases will be analyzed using 
Statistical Analysis System Software (SASS). The primary outcome for this study will be 
evaluated using bivariate analysis between each group as well as the control group using 
a Chi-square model. These groups will then be compared within each other using a 
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multivariate analysis, the categorical outcomes using multiple logistic regression. The 
secondary outcome of prescription fill type and positive C-SRSS will use a bivariate 
analysis within each group and the control group using a Chi-squared model. These 
groups will then be compared with each other again using the multivariate analysis, as 
described above. The secondary outcome of chronic pain and positive C-SRSS will be 
compared using bivariate analysis, and the McNemar test will be used for these groups 
with a simple logistic regression used to control for confounders.  
 These statistics along with confounders and matching are found in Table 1 
3.10 TIMELINE AND RESOURCES 
 This proposed study will take place over six months. The first two months will be 
the collection of the data from VA databases, and the following three months will be data 
analysis. The final month will be to result and write a manuscript for publication. This 
study will require access to the previously outlined VA databases with access through the 
West Haven VA. Computers with two-factor authentication will be required for data 
storage and analysis. The primary investigator (PI) will be Dr. Juliette Spelman, MD, and 
the co-primary investigator (co-PI) will be Nicholas Drews, PA-S2. The PI will handle 
accessing and retrieving all relevant data from VA databases, and the co-PI will run all 
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CHAPTER 4: CONCLUSION 
4.1 ADVANTAGES AND DISADVANTAGES 
 One of several advantages of this proposed study is that all the data needed for 
analysis is already collected and easily accessed through VA databases. These databases 
dramatically reduce the human resources and time needed to conduct a study of this 
magnitude. The most significant time component in this study would be for statistical 
processing and matching of datasets. Another advantage of this study is that it will 
encompass all VA health records, with the three state exceptions, as previously noted. 
Having a study that will capture almost all VA health centers nationally allows the study 
to be very generalizable to future VA healthcare initiatives. This broad scope also allows 
the study to be generalizable to the non-veteran population since tools like the C-SRSS 
and PDMPs are available nationwide. It is also very generalizable since it has been 
established that the same causes of suicidal ideation in the veteran population exist in the 
non-veteran population. A significant advantage of this study is that multiple well-
established confounders can be matched between participants with near-perfect quality. 
This matching is not nearly as well achieved in a prospective study since the recruitment 
processes cannot be as comprehensive. 
 This study does have some key disadvantages as well. One of the most notable 
disadvantages is that there is no guarantee that veterans will have received a mental 
health screening within the 180 days of an opioid prescription. This gap in participant 
coverage leaves open a possibility for unaccounted for confounders. Additionally, since 
this is a retrospective study, there cannot be any inferences made about causality to the 
relationship between opioid prescriptions and suicidal ideation, if one is uncovered. The 
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only relationship that could be inferred from this study is that there is a relationship, 
which would likely be one along the causal pathway that has not been discovered.  
4.2 FEASIBILITY 
 This study is very feasible since the datasets already exist in VA databases. The 
factor most limiting to feasibility is the processing time for the data and receiving IRB 
approval from the VA.  
4.3 MECHANISTIC SIGNIFICANCE 
 This study will have low mechanistic significance. This significance is limited by 
the study design and not being able to account for all possible confounders without 
stricter recruiting guidelines.  
4.4 CLINICAL SIGNIFICANCE 
 This would be the first study of its kind to evaluate the relationship between 
opioid prescription and dosage and suicidal ideation. The clinical significance of this 
study is significant, though with some caveats. If the relationship proposed in this study 
were shown to exist, then it would provide the evidence to support increased suicidal 
ideation screening for patients receiving opioids. The more patients appropriately 
screened, the better opportunity for lethal means reduction and engagement in mental 
health follow-up, potentially reducing risk for suicide completion. Currently, there is still 
a gap in identifying who needs more careful screening and intervention that this study 
could help to close. The risk of this is that there may be an increased stigma for the 
prescribing of opioids for patients who would otherwise benefit from them, such as 
hospice and palliative care patients. This stigma must also be balanced with the risks 
inappropriately posed by deprescribing opioids since this can also pose a risk to patients.  
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4.5 FUTURE DIRECTIONS 
 This study lays the foundation for further prospective analysis that would better 
identify confounders that may lie at the heart of this relationship. This study could also be 
used as the basis for enhanced screening tools using existing VA systems such as 
STORM and CRYSTAL. These tools can already notify clinicians if there is a potentially 
unsafe treatment course, and with the results of this study, these tools could be modified 




























APPENDIX D: Morphine equivalent daily dose calculation 
Morphine equivalent daily dose = Converted size in mg X Total quantity/Day supply 
Conversion factors:  
Codeine = 0.15 
Hydrocodone = 1 
Hydromorphone = 4 
Hydromorphone (injected) = 16 
Oxycodone = 1.5 
Oxymorphone = 0.56 
Morphine (injected) = 3 
 
To convert: take the daily dose of prescribed opioid and multiply by the conversion factor 
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APPENDIX E: VA IRB Process 
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Table 1 Patient demographics and individual statistical analysis  
Patient and Treatment Characteristics Exposure Control P value
Prescribed Daily Opioid Dose
 0 mg/d n/a (%) Chi-square
 1 to < 20 mg/d (%) n/a Chi-square
 20 to < 50 mg/d (%) n/a Chi-square
 50 to < 100 mg/d (%) n/a Chi-square
 100+ mg/d (%) n/a Chi-square
Physical Conditions
     Chronic pain (%) (%) Chi-square
     Acute pain/injury (%) (%) Chi-square
     Traumatic brain injury (%) (%) Chi-square
     Neuropathy (%) (%) Chi-square
      Psychogenic pain (%) (%) Chi-square
     Cancer (%) (%) Chi-square
     COPD (%) (%) Chi-square
     Any sleep apnea (%) (%) Chi-square
Charlson Comorbidity Index Score
 0 (%) (%) Chi-square
 1 (%) (%) Chi-square
 2+ (%) (%) Chi-square
Psychiatric Conditions
     Depression (%) (%) Chi-square
 PTSD (%) (%) Chi-square
     Any anxiety disorder (%) (%) Chi-square
 Psychotic Disorders Dx (any) (%) (%) Chi-square
 Opioid use disorder Dx (ever) (%) (%) Chi-square
     Bipolar disorder (%) (%) Chi-square
Demographics
 Male (%) (%) Chi-square
     Age Mean (sd) Mean (sd) t-test
Race
     White (%) (%) Chi-square
     Black (%) (%) Chi-square
     Hispanic Ethnicity (%) (%) Chi-square
     Other (%) (%) Chi-square
Branch of service
     Marines (%) (%) Chi-square
     Army (%) (%) Chi-square
     Navy (%) (%) Chi-square
     Air Force (%) (%) Chi-square
     Coast Guard (%) (%) Chi-square
Comission Status
     Officer (%) (%) Chi-square
     Enlisted (%) (%) Chi-square
Medication use (any)
     Benzodiazepines (%) (%) Chi-square
     SSRI (%) (%) Chi-square
     SNRI (%) (%) Chi-square
     Hypnotics (%) (%) Chi-square
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Table 2 Inclusion and exclusion criteria 
  
Inclusion citeria Exclusion Criteria
OIF/OEF Veteran Current substance use disorder
Received opioid prescription Hopspice or paliative care
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